Active Ingredient(s):Ramucirumab FDA Approved: * April 21, 2014 Pharm Company: *ELI LILLY AND CO Category:Cancer
Ramucirumab (LY3009806, IMC-1121B, trade name Cyramza) is a fully human monoclonal antibody (IgG1) developed for the treatment of solid tumors. This drug was developed by ImClone Systems Inc. It was isolated from a native phage display library from Dyax.
1 Approved uses
3 Side effects
5.1 Mechanism of action
6 Clinical trials
8 External links
* May have multiple approval dates, manufacturers, or labelers. 1 Discussion